Your browser doesn't support javascript.
Prevalence of anti-SARS-CoV-2 IgG antibodies among Kenyan blood donors between June and August 2021
Journal of Public Health in Africa ; 13:12-13, 2022.
Article in English | EMBASE | ID: covidwho-2006934
ABSTRACT
Introduction/

Background:

Previous reports have estimated national seroprevalence of anti-SARS-CoV-2 IgG antibodies among blood donors in Kenya at 4.3% (April-June 2020), 9.1% (August-September 2020), and 48.5% (January-March 2021). Here we describe seroprevalence in the period June-August 2021 when COVID-19 vaccine coverage was 2.5% in the adult population in Kenya.

Methods:

We undertook a cross-sectional descriptive study to estimate prevalence of anti-SARS-CoV-2 IgG antibodies using residual plasma from the 6 regional transfusion centres in Kenya. Samples with complete donor demographic data were included and analysed using an anti-spike IgG enzyme- linked immunosorbent assay with validated specificity of 99.0% and sensitivity of 92.7%. Bayesian multilevel regression with poststratification was used to obtain seroprevalence estimates and 95% credible intervals (Crl) adjusted for age, sex, and region of residence referenced against national 2019 census data for individuals aged 16-64 years. Results were also adjusted for test performance.

Results:

Of 7601 available plasma samples donated between 2nd June 2021 and 7th August 2021, 7139 (93.1%) were included in the analysis. Males comprised 5555 (78.8%) of the study population, while 4304 (60.3%) samples were from individuals aged 16-24 years. Crude seroprevalence was 67.2% (95% CrI, 66.1%- 68.3%). Overall Bayesian population-weighted, test-adjusted seroprevalence was 73.2% (95%CrI, 69.8-77.2%). Seroprevalence ranged from 69.9% among donors aged 35-44 years to 76.3% in the 16-24-year age group. We found no difference in seroprevalence by sex. Regional seroprevalence ranged from 58.9% in the coastal region (excluding Mombasa) to 82.5% in Nairobi. Impact Local governments are making efforts to improve vaccine coverage while faced with limited access to the vaccines. These findings may guide targeted vaccine deployment through prioritization of vulnerable populations with lower seropositivity.

Conclusion:

SARS-CoV-2 has continued to spread rapidly across Kenya, infecting three-quarters of the adult population sampled through blood donation. The high seroprevalence observed is consistent with reports from other regions in sub-Saharan Africa and implies substantial infection-induced immunity that may mitigate the impact of low vaccine coverage.
Keywords
Search on Google
Collection: Databases of international organizations Database: EMBASE Type of study: Observational study Language: English Journal: Journal of Public Health in Africa Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS

Search on Google
Collection: Databases of international organizations Database: EMBASE Type of study: Observational study Language: English Journal: Journal of Public Health in Africa Year: 2022 Document Type: Article